Ms Eibhlin Mulroe

Ms Eibhlin Mulroe

PPI Council Member

Ms Mulroe was appointed CEO of the Cancer Trials Ireland (formerly ICORG) in June 2015 and manages a cross functional team in Head Office of 50 staff including clinical operations, Data & Statistics, Quality and Pharmacovigilance. She works to implement the strategic plan in consultation with the Dr Jonathan Westrup, Chair of the Board of Directors and Prof Bryan Hennessy, Clinical Lead.

Under her leadership, Cancer Trials Ireland rebranded, moved to a bespoke office space, commissioned an Economic Impact Report (DFK) on cancer trial activity in Ireland, worked with InterTrade Ireland in 2017/8 to revisit the all-Ireland cancer trials network and established a Patient Advocate Advisory Group.

Cancer Trials Ireland is a not for profit organisation with a mission to bring Irish patients early access to the latest cancer treatments through research and to establish Ireland as a recognised centre of high quality translational and clinical research.

Ms Mulroe sits on the Ehealth Ireland Committee which supports the implementation of the Irish government’s Ehealth Strategy.

She is a member of the Royal Irish Academy Life Sciences Committee. A member of the Governance Committee of Blood Cancer Network Ireland (BCNI). The Irish Health Research Forum appointed Ms Mulroe to their Steering Group in 2018. A member of the Advisory Board of the Cork Clinical Research Centre.

She leads the organisations advocacy agenda where the National Cancer Strategy has dominated discussions with relevant individuals at the Department of Health, IDA, National Cancer Control Programme (NCCP) and HSE.

In her early career Ms Mulroe worked in Irish Politics and then the NGO sector where she worked as CEO of the Asthma Society of Ireland. She then worked as an Account Manager with MedMedia.

In July 2007, she became the first CEO of the Irish Platform for Patients’ Organisations, Science and Industry (IPPOSI) and Chair of a Task Force in the European Patient Academy for Therapeutic Innovation (EUPATI).

Ms Mulroe was appointed by the Irish Minister for Health to the Department of Health Steering Group on Rare Disease Policy in 2010, she represented patients on the Health Information and Quality Authority (HIQA) Research Ethics Advisory Board, HIQA, HTA Advisory Board and was a member of the HSE Patient’s Forum. She served as the patient representative on the Legal Consultative Panel of the Irish Medicines Board (now HPRA).

Ms Mulroe led IPPOSI to partake in 2 EC Research Consortiums, BBMRI and EUPATI, the latter is a unique initiative to develop an EU Patient Academy.

Ms Mulroe has a BSocSc Hons from Queens University Belfast and is an MBA graduate from the Smurfit Business School, University College Dublin.

3D mammosphere culture of breast epithelial cell line MCF10A.

Courtesy of Dr. Emer Bourke, NUI Galway

Phospho-Akt expression and localisation

Mediated by VEGF in A549 lung cancer cells. Visualised by high content image analysis.

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

Metaphase chromosome spread of Jurkat T-lymphoma cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

Apoptosis assessment of SKMES-1 lung cancer cells

Using a multiparameter apoptosis staining kit, showing cell nuclei (blue), actin (green) and mitochondrial activity (orange).

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

HeLa Cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

IACR & EACR Joint Conference 2020

26 — 28 February 2020 at Galway Bay Hotel, Galway

Mitotic Chronic Myelogenous Leukaemia K562 Cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

Cell to Cell Tweeting

Via nanoparticles (red) in Triple Negative Breast Cancer (TNBC)

Courtesy of Sinéad Lindsay, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD) Ireland.

Confocal Microscopy Analysis

Of phospho-Akt expression in H460 lung cancer cells in response to hypoxia (0.5% O2).

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

Donate to Cancer Research

All donations to the IACR go directly towards supporting early-stage oncology scientific researchers in their work.

IACR 2023 Carer’s Bursary €300

Apply for funding towards the additional costs of care while attending conference. Five Bursaries Available. 

Registration/ Membership for IACR 2023

Registration for the 59th Annual Conference in the Radisson Blu hotel, Athlone is Now Open.

EACR Membership is Included

The IACR is an affiliated national society and its members benefit from full membership of the EACR.

Late Breaking Abstracts in Now OPEN!

Biomedical Session Abstracts

Deadline: Midnight, Friday, 20th January 2023

Please note:
- Patrick Johnston Lay submission category is now closed
- Late Breaking Abstracts submitted to the Biomedical Sessions will be considered for Display Poster Presentation. 

Social Nursing and Allied Health (SNAH) Abstracts

Deadline: Midnight, Monday, 9th January 2023

SNAH abstract submissions will remain open until Monday 9th January.

Any questions?
Please contact Sinead on: sinead@sineadcassidy.com

Contact Us

9 + 10 =

Contact Us
Irish Association for Cancer Research
9A Coolkill, Sandyford, Dublin 18

T: +353 (0)1 295 8859
E: info@iacr.ie

Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations.

Registered Charity Number (RCN): 20030117

Design by patterns.ie
© 2022